EFFECT OF CYTOCHROME P450 2C9 GENE POLYMORPHISMS ON INDIVIDUAL SENSITIVITY TO GLICLAZIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS


如何引用文章

全文:

详细

Cytochrome P450 2C9, encoded by the gene CYP2C9 , is a key enzyme for the metabolism of most sulfonylurea (SU). It is known that the polymorphisms CYP2C9*2 and CYP2C9*3 are associated with decreased activity of cytochrome, which leads to an increase in plasma concentrations of SU and reduction in its clearance. The aim of the study was to assess the impact CYP2C9 polymorphisms on individual sensitivity to gliclazide in patients with type 2 diabetes. The study included 74 patients with newly diagnosed diabetes. For all patients gliclazide in a dose of 30 or 60 mg/day was prescribed. Dose titration was carried out for 6 months of observation. If necessary other glucose-lowering therapy (a combination of drugs or insulin) were prescribed. Following the results of study, all patients had achieved the target values of Hb A1c. In comparison with patients who had a polymorphic allele in the gene, patients with wild-type CYP2C9 had lower effective dose of gliclazide, more often required prescription of large (90-120 mg) doses of drug or other antihyperglycemic therapy. Conclusion: The presence of a polymorphic allele in the gene CYP2C9 in homo- or heterozygous state is associated with a decrease in the effective dose of gliclazide, used as monotherapy in patients with type 2 diabetes.

作者简介

M Abulula

North-Western State Medical University named after I.I.Metchnikov

V Baranov

North-Western State Medical University named after I.I.Metchnikov

N Vorokhobina

North-Western State Medical University named after I.I.Metchnikov

参考

  1. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Position Statement // Diabetes Care. - 2013. - Vol. 36. - Suppl. 1. - P. 67-74.
  2. Desai N.R., Shrank W.H., Fischer M.A. et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. // Am. J. Med. - 2012. - Vol. 125. - № 302. - P. e301-e307.
  3. Ashcroft F.M., Rorsman P. Electrophysiology of the pancreatic beta-cell rog Biophys. Mol. Biol. - 1989. - Vol. 54. - P. 87-143.
  4. Proks P., Reimann F., Green N., Gribble F., Ashcroft F. Sulfonylurea Stimulation of Insulin Secretion // Diabetes. - 2002. - Vol. 51. - Suppl. 3. - P. S368-S376.
  5. Gribble F.M., Davis T.M.E., Higham C.E., Clark A., Ashcroft F.M. The antimalarial agent mefloquine inhibits ATP-sensitive K-channels // Br. J. Pharmacol. - 2000. - Vol. 131. - P. 756-760.
  6. Gribble F.M., Tucker S.J., Seino S., Ashcroft F.M. Tissue specificity of sulphonylureas: studies on cloned cardiac and beta-cell KATP channels // Diabetes. - 1998. - Vol. 47. - P. 1412-1418.
  7. Proks P., Reimann F., Green N., Gribble F., Ashcroft F. Sulfonylurea Stimulation of Insulin Secretion // Diabetes. - 2002. - Vol. 51. - Suppl. 3. - P. S368-S376.
  8. Koster J.C., Sha Q., Nichols C.G. Sulfonylurea and K-channel opener sensitivity of KATP channels: functional coupling of Kir6.2 and SUR1 subunits // J. Gen. Physiol. - 1999. - Vol. 114. - P. 203-213.
  9. Krauter T., Ruppersberg J.P., Baukrowitz T. Phospholipids as modulators of KATP channels: distinct mechanisms for control of sensitivity to sulphonylureas, K-channel openers, and ATP // Mol. Pharmacol. - 2001. - Vol. 59. - P. 1086-1093.
  10. DeFronzo RA. Pharmacologic therapy for Type 2 diabetes mellitus. // Ann. Intern. Med. - 1999. - Vol. 131. - №4. - P. 281-303.
  11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). // Lancet. - 1998. - Vol. 352. - P. 837-853.
  12. Matthews D.R., Cull C.A., Stratton I.M., Holman R.R., Turner, R.C. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. // Diabet. Med. - 1998. - Vol. 15. - P. 297-303.
  13. Kirchheiner J., Brockmoller J., Meineke I. et al. Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers // Clinical Pharmacology and Therapeutics. - 2002. - Vol. 71. - №4. - P. 286-296.
  14. Kirchheiner J., Bauer S., Meineke I. et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers // Pharmacogenetics. - 2002. - Vol. 12. - № 2. - P. 101-109.
  15. Zhou K., Donnelly L., Burch L. et al. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a go-DARTS study // Clinical Pharmacology and Therapeutics. - 2010. - Vol. 87. - № 1. - P. 52-56.
  16. Becker M. L., Visser L. E., Trienekens P. H., Hofman A., Van Schaik R. H. N., Stricker B. H. C. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus // Clinical Pharmacology and Therapeutics. - 2008. - Vol. 83. - № 2. - P. 288-292.
  17. Swen J. J., Wessels J. A. M., Krabben A., Assendelft W. J. J., Guchelaar H.-J. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with type 2 diabetes mellitus // Pharmacogenomics. - 2010. - Vol. 11. - № 11. - P. 1517-1523

版权所有 © Abulula M., Baranov V.L., Vorokhobina N.V., 2015

Creative Commons License
此作品已接受知识共享署名 4.0国际许可协议的许可

##common.cookie##